ProtoKinetix, Inc.

ProtoKinetix, Inc.

ProtoKinetix, Inc. is a publicly traded biotechnology firm headquartered in Canada, listed on the OTC Markets under the symbol PKTX. The company's primary asset is its patented anti-aging glycoprotein (AAGP) platform, which targets inflammation and oxidative stress associated with aging. ProtoKinetix was founded with the goal of commercializing AAGP-based therapies for a range of age-related diseases, including Duchenne muscular dystrophy and ischemic stroke. The firm's strategy centers on advancing its lead candidate through preclinical and early clinical development, with a focus on securing partnerships or licensing agreements for later-stage trials. ProtoKinetix does not currently report a dedicated investment portfolio or external capital management activities beyond its own operational funding. The company's pipeline includes programs in muscular dystrophy, stroke, and other inflammatory conditions, though none have reached Phase II trials as of 2025. ProtoKinetix operates as a small-cap public company with a market capitalization under $10 million as of mid-2025. The firm does not disclose separate assets under management for investment activities, and its funding has historically come from equity offerings and grants. No philanthropic foundation or operating business subsidiaries have been publicly identified. The core structural differentiator for ProtoKinetix is its status as a publicly traded biotechnology company with a single-platform focus on AAGP, rather than a diversified portfolio of assets. The firm's governance includes a board of directors and executive team responsible for corporate strategy, but no family office or external investment vehicle has been publicly linked to its operations.